Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has reported that the company is discontinuing clinical development of PRX-00023 due to lack of significant efficacy shown in the recently completed Phase IIb trial in patients with major depressive disorder.
Subscribe to our email newsletter
Michael Kauffman, CEO of Epix, said: “While PRX-00023 continued to show a highly desirable safety and tolerability profile, we are disappointed in the overall results observed in our recently completed Phase IIb trial in major depressive disorder. In light of these results, we have made the strategic decision to discontinue further development of this product candidate.”